{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:37:20Z","timestamp":1791380240604,"version":"4.3.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T00:00:00Z","timestamp":1301961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00280-011-1612-1","type":"journal-article","created":{"date-parts":[[2011,4,4]],"date-time":"2011-04-04T15:24:54Z","timestamp":1301930694000},"page":"1397-1403","source":"Crossref","is-referenced-by-count":33,"title":["Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies"],"prefix":"10.1007","volume":"68","author":[{"given":"P.","family":"Sch\u00f6ffski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Dumez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Miguel-Lillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Soto-Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,5]]},"reference":[{"key":"1612_CR1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/978-3-540-30880-5_16","volume":"43","author":"G Faircloth","year":"2006","unstructured":"Faircloth G, Cuevas C (2006) Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 43:363\u2013379","journal-title":"Prog Mol Subcell Biol"},{"key":"1612_CR2","unstructured":"Baird R, Clarke P, Workman P (2005) ES-285, a novel marine anticancer agent: Investigation of mechanism of action using gene expression microarrays. AACR Meet Abstr 2005:970"},{"key":"1612_CR3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejphar.2008.02.011","volume":"584","author":"AM Sanchez","year":"2008","unstructured":"Sanchez AM, Malagarie-Cazenave S, Olea N, Vara D, Cuevas C, Diaz-Laviada I (2008) Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. Eur J Pharmacol 584:237\u2013245","journal-title":"Eur J Pharmacol"},{"key":"1612_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0304-3835(99)00428-0","volume":"152","author":"R Cuadros","year":"2000","unstructured":"Cuadros R, Montejo de Garcini E, Wandosell F, Faircloth G, Fernandez-Sousa JM, Avilla J (2000) The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett 152:23\u201329","journal-title":"Cancer Lett"},{"key":"1612_CR5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10495-006-0573-z","volume":"12","author":"M Salcedo","year":"2007","unstructured":"Salcedo M, Cuevas C, Alonso JL, Otero G, Faircloth G, Fernandez-Sousa JM, Avila J, Wandosell F (2007) The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. Apoptosis 12:395\u2013409","journal-title":"Apoptosis"},{"key":"1612_CR6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1535-7163.MCT-08-1167","volume":"8","author":"RD Baird","year":"2009","unstructured":"Baird RD, Kitzen J, Clarke PA, Planting A, Reade S, Reid A, Welsh L, Lopez Lazaro L, de las Heras B, Judson IR, Kaye SB, Eskens F, Workman P, de Bono JS, Verweij J (2009) Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol Cancer Ther 8:1430\u20131437","journal-title":"Mol Cancer Ther"},{"key":"1612_CR7","doi-asserted-by":"crossref","unstructured":"Vilar E, Gr\u00fcnwald V, Sch\u00f6ffski P, Singer H, Salazar R, Iglesias JL, Casado E, Cullell-Young M, Baselga J, Tabernero J (2010) A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors. Invest New Drugs. doi: 10.1007\/s10637-010-9529-9","DOI":"10.1007\/s10637-010-9529-9"},{"key":"1612_CR8","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ffski P, Gr\u00fcnwald V, Giaccone G et al (2008) Outcome of three Phase I trials of the marine compound ES-285 (3 hour infusion) in patients with refractory solid tumors. Eur J Cancer, 6(12), ENA Meet Abstr 176","DOI":"10.1016\/S1359-6349(08)72108-6"},{"key":"1612_CR9","unstructured":"Massard C, Majem M, Soria J-C, Salazar R, Deutsch E, Garcia M, Oaknin A, Soto A, de las Heras B, Armand J-P (2007) Phase I (3 hour infusion every 3\u00a0weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumors. AACR Meet Abstr 2007:A4"},{"key":"1612_CR10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1612_CR11","first-page":"246","volume":"59","author":"MW Brok Den","year":"2005","unstructured":"Den Brok MW, Nuijen B, Meijer DM, Millan E, Manada C, Beijnen JH (2005) Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl. PDA J Pharm Sci Technol 59:246\u2013257","journal-title":"PDA J Pharm Sci Technol"},{"key":"1612_CR12","first-page":"21","volume":"61","author":"MW Brok Den","year":"2006","unstructured":"Den Brok MW, Nuijen B, Garcia JL, Miranda E, Calvo P, Manada C, Beijnen JH (2006) Compatibility and stability of the novel anticancer agent ES-285\u00a0\u00d7\u00a0HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices. Pharmazie 61:21\u201324","journal-title":"Pharmazie"},{"key":"1612_CR13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/jms.469","volume":"38","author":"E Stokvis","year":"2003","unstructured":"Stokvis E, Nan-Offeringa L, Rosing H, Lopez-Lazaro L, Acena JL, Miranda E, Lyubimov A, Levine BS, D\u2019Aleo C, Schellens JH, Beijnen JH (2003) Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry. J Mass Spectrom 38:548\u2013554","journal-title":"J Mass Spectrom"},{"issue":"4","key":"1612_CR14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s002800050983","volume":"44","author":"AA Geldof","year":"1999","unstructured":"Geldof AA, Mastbergen SC, Henrar RE, Faircloth GT (1999) Cytotoxicity and neurocytotoxicity of new marine anticancer agents using in vitro assays. Cancer Chemother Pharmacol 44(4):312\u2013318","journal-title":"Cancer Chemother Pharmacol"},{"issue":"33","key":"1612_CR15","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2174\/138161207782360573","volume":"13","author":"C Le Tourneau","year":"2007","unstructured":"Le Tourneau C, Raymond E, Faivre S (2007) Aplidine: a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr Pharm Des 13(33):3427\u20133439","journal-title":"Curr Pharm Des"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1612-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1612-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1612-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T17:16:31Z","timestamp":1560100591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1612-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,5]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1612-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,5]]}}}